Bisamide Malonate Antagonist for Allergic Rhinitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drugs targeting histamine receptor types 3 and 4 for treating allergic rhinitis lack selectivity and often cause central nervous system side effects due to crossing the blood-brain barrier, leading to undesirable side effects.
Innovation Solution
Development of a histamine H3/H4 receptor antagonist, N,N′-bis(2-(1H-imidazol-5-yl)ethyl)malonamide, which is effective in suppressing the activity of histamine receptors and suitable for oral and intranasal administration, reducing itch and allergic symptoms without crossing the blood-brain barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If histamine H3 and H4 receptor antagonists are used to treat allergic rhinitis, then therapeutic effect is improved, but central nervous system side effects occur due to blood-brain barrier penetration
Solution Approach 1:
The patent applies local quality by designing a compound with selective affinity for peripheral H3 and H4 receptors while avoiding central nervous system penetration. The molecular structure is optimized to interact specifically with peripheral histamine receptors in nasal mucosa and immune cells, creating a spatial distinction between therapeutic action site and side effect avoidance zone.
Solution Approach 2:
The patent uses the blood-brain barrier as an intermediary element that the compound deliberately does not cross. By designing the molecule with specific physicochemical properties (molecular weight, lipophilicity, hydrogen bonding capacity), it exploits the blood-brain barrier as a protective mediator that prevents central nervous system exposure while allowing peripheral therapeutic action.
2Adaptability or versatility
If non-selective histamine receptor antagonists are used, then broad therapeutic coverage is achieved, but selectivity and safety profile deteriorate
Solution Approach 1:
The patent achieves universality by creating a dual-acting compound that simultaneously targets both H3 and H4 receptor subtypes. The molecular structure contains pharmacophoric elements that can interact with multiple histamine receptor types, providing broad therapeutic coverage for various allergic conditions through a single agent.
Solution Approach 2:
The patent applies local quality by designing differential binding characteristics for H3 and H4 receptors. The compound's molecular structure is optimized to interact specifically with peripheral H3 and H4 receptors while avoiding central nervous system H3 receptors, creating spatial and selective distinction in receptor engagement.
3Reliability
If H3 receptor antagonists cross the blood-brain barrier, then central H3 receptor blockade is achieved, but undesirable side effects such as depression and sleep disturbances occur
Solution Approach 1:
The patent applies the extraction principle by removing the ability of the compound to cross the blood-brain barrier while retaining peripheral H3 receptor antagonistic activity. The molecular structure is modified to eliminate central nervous system penetration capability, extracting only the desired peripheral therapeutic effect and leaving behind the harmful central side effects.
Solution Approach 2:
The patent applies local quality by creating a compound with restricted spatial action to peripheral tissues. The molecular properties are optimized to ensure the drug acts locally in nasal mucosa and peripheral immune cells while being excluded from central nervous system tissues, creating a spatial boundary between therapeutic and harmful effects.
Data Source
AI summary
The invention relates to the therapy of diseases associated with the activity of histamine receptors, in particular for the treatment of allergic diseases, preferably the therapy of perennial and persistent allergic rhinitis, itch, as well as a number of other diseases associated with the activity of histamine receptor type 3 and/or 4, using compound N,N′-bis(2-(1H-imidazol-5-yl)ethyl)malonamide.This compound, as well as pharmaceutically acceptable salts, hydrates, or solvates thereof, is an antagonist of histamine receptor type 3 and/or 4. The invention also relates to pharmaceutical compositions containing a therapeutically effective amount of Compound I.